Your session is about to expire
← Back to Search
Antibiotics for Cholangitis
Study Summary
This trial will help researchers understand if giving antibiotics to people before they undergo the ERCP procedure can help prevent cholangitis, a condition where the bile ducts become inflamed.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Antibiotic arm
- Group 2: No Antibiotic arm
Frequently Asked Questions
Are seniors aged 70 and over being considered for inclusion in this research project?
"Applicants must be between 18-90 years old to qualify for this study, outlined in the conditions of participation."
Has the FDA sanctioned Antibiotic arm for therapeutic use?
"The safety of the Antibiotic arm has been rated a 3, as it is part of Phase 4 trials which indicates approval."
Is recruitment for this research still happening?
"This medical experiment has been actively recruiting participants since March 29th 2017 and is still seeking individuals, as evidenced by its most recent update on December 6th 2021."
How many participants are currently involved in this research endeavor?
"Affirmative. According to clinicaltrials.gov, this experiment was initially posted on March 29th 2017 and is actively seeking participants; the most recent edit occurred December 6th 2021. The research requires 200 people at a single location."
What bacterial infections most regularly respond to antibiotic treatment?
"Antibiotic arm therapy is regularly utilized to treat abscesses, as well as pyoderma, post-operative infection prevention, and prophylactic defense against neonatal conjunctivitis caused by gonorrhoea."
What qualifications must prospective participants meet for this clinical trial?
"This clinical trial is interested in recruiting approximately 200 individuals who are afflicted with cholangitis and between 18 to 90 years old."
Share this study with friends
Copy Link
Messenger